Research and development teams amass huge quantities of complex data which, if exploited correctly, can be a useful information source to improve decision-making and drive innovation.
It is estimated that one in five human cancers involve RAS mutations. Although once considered undruggable, this blog looks at recent advances in RAS inhibitors and emerging therapies.
We are in the midst of a therapeutic revolution, according to the authors of a recent review article in Frontiers in Bioengineering and Biotechnology. They were commenting on the rapid expansion of RNA therapeutics in modern research and clinical development, driven in part by interest in RNA COVID-19 vaccines in the ongoing SARS-CoV-2 pandemic.
